ArticleBJUI compass2025
Comparison of the oncological and functional outcomes among patients with high-risk upper tract urothelial cancer undergoing segmental ureterectomy based on tumour location.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Segmental ureterectomy (SU) represents a viable alternative to radical nephroureterectomy (RNU) for the management of distal ureteral tumours when technically feasible. However, SU of the proximal two-thirds of the ureter is associated with higher failure rates compared to distal ureteral tumours. This study aims to compare oncologic outcomes and renal function in patients undergoing SU for tumours located in the distal versus proximal ureter. Methods: Prospective, non-randomized cohort study, which included adult patients with high-risk cT2-3 cN0-1 M0 ureteral tumours deemed suitable for SU, with preoperative affected kidney function > 15 ml/min. Patients were treated at a reference centre between March 2019 and March 2023. Patients were divided into two cohorts based on the primary tumour location: distal or proximal two-thirds of the ureter. All patients received neoadjuvant chemotherapy (Gem-Cis) and cases that underwent RNU were excluded from the study. Kaplan-Meier analysis was employed to evaluate local- recurrence-free survival (L-RFS), progression-free survival (PFS) and overall survival (OS). Results: A total of 41 patients underwent SU (21/20 proximal/distal location). The cohorts were matched by age, sex, BMI, ECOG status, T-stage, pN status, tumour length, preoperative eGFR, primary pathology and positive cytology (p > 0.05). Following segmental ureterectomy, all patients with distal ureteral tumours underwent neostomy reconstruction. In the proximal ureter group, reconstruction techniques included end-to-end anastomosis in 9 (43%), Andersen-Heinz plasty in 8 (38%) and ureter-ileum interposition in 4 cases (19%).No statistically significant differences were observed between the two cohorts in terms of surgery duration, average blood loss, Grade ≥3 complications, length of postoperative stay or 30-day readmission rate (p > 0.05). Postoperative eGFR was similar between the groups (60.4 ± 8.5 vs. 59.4 ± 11.4; p = 0.81). Furthermore, no significant differences were found between patients with proximal versus distal ureteral tumours in terms of 2-year L-RFS (72% vs. 85%; p = 0.29), PFS (85% vs. 77%; p = 0.69) or OS (65% vs. 77%; p = 0.43). Conclusion: The current study demonstrates that segmental ureterectomy provides comparable oncologic outcomes and renal function preservation for both proximal and distal ureteral cancer. SU can be considered a safe and effective kidney-sparing alternative to radical nephroureterectomy in high-risk cases, regardless of tumour location.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.